Article information
Full text is only aviable in PDF
References
[1]
RM Jasmer, P Nahid, PC Hopewell.
Clinical practice. Latent tuberculosis infection.
N Engl J Med, 347 (2002), pp. 1860-1866
[2]
E Lee, RS Holzman.
Evolution and current use of the tuberculin test.
Clin Infect Dis, 34 (2002), pp. 365-370
[3]
P Miret, JM Pina, S Juncosa.
Tuberculin reactivity in bacillus Calmette-Guérin vaccinated subjects.
Tuber Lung Dis, 77 (1996), pp. 52-58
[4]
RE Huebner, MF Schein, JB Bass Jr.
The tuberculin skin test.
Clin Infect Dis, 17 (1993), pp. 968-975
[5]
JM Pina, A Domínguez, J Alcaide, J Álvarez, N Campos, N Díez, et al.
La respuesta a la prueba de tuberculina en enfermos tuberculosos.
Arch Bronconeumol, 38 (2002), pp. 568-573
[6]
D Menzies.
Interpretation of repeated tuberculin tests. Boosting, conversion and reversion.
Am J Respir Crit Care Med, 159 (1999), pp. 15-21
[7]
A Lalvani, P Nagvenkar, Z Udwadia, AA Pathan, KA Wilkinson, JS Shastri, et al.
Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians.
J Infect Dis, 183 (2001), pp. 469-477
[8]
P Andersen, ME Munk, JM Pollock, TM Doherty.
Specific immunebased diagnosis of tuberculosis.
Lancet, 356 (2000), pp. 1099-1104
[9]
J Domínguez, J Ruiz-Manzano.
Prueba de la tuberculina: ¿es la hora del cambio?.
Arch Bronconeumol, 42 (2006), pp. 47-48
[10]
J Domínguez, J Ruiz-Manzano, M de Souza-Galvão, I Latorre, C Milà, S Blanco, et al.
Comparison of two commercially available interferon-gamma blood tests for immunodiagnosis of tuberculosis infection.
Clin Vaccine Immunol, 15 (2008), pp. 168-171
[11]
D Menzies, M Pai, G Comstock.
Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.
Ann Intern Med, 146 (2007), pp. 340-354
[12]
L Richeldi.
An update on the diagnosis of tuberculosis infection.
Am J Respir Crit Care Med, 174 (2006), pp. 736-742
[13]
CR Horsburgh Jr.
Priorities for the treatment of latent tuberculosis infection in the United States.
N Engl J Med, 350 (2004), pp. 2060-2067
[14]
American Thoracic Society.
Targeted tuberculin testing and treatment of latent tuberculosis infection.
Am J Respir Crit Care Med, 161 (2000), pp. S221-S247
[15]
M Korzeniewska-Kosella, J Krys, N Muller, W Blas, E Allen, JM FitzGerald.
Tuberculosis in young adults and the elderly: a prospective comparison study.
Chest, 106 (1994), pp. 28-32
[16]
S Waite, J Jeudy, CS White.
Acute lung infections in normal and immunocompromised hosts.
Radiol Clin N Am, 44 (2006), pp. 295-315
[17]
BE Jones, R Ryu, Z Yang, MD Cave, JM Pogoda, M Otaya, et al.
Chest radiographic findings in patients with tuberculosis with recent or remote infection.
Am J Respir Crit Care Med, 156 (1997), pp. 1270-1273
[18]
E Geng, B Kreiswirth, J Burzynski, NW Schluger.
Clinical and radiographic correlates of primary and reactivation tuberculosis.
JAMA, 293 (2005), pp. 2740-2745
[19]
JA Caminero Luna.
Guía de la tuberculosis para médicos especialistas. International union against tuberculosis and lung disease, Imprimerie Chirat, (2003),
[20]
JC Palomino, S Cardoso Leão, V Ritacco.
Tuberculosis 2007. From basic science to patient care.
[21]
JA Caminero.
Management of multidrug-resistant tuberculosis and patients in retreatment.
Eur Respir J, 25 (2005), pp. 928-936
[22]
SJ Kim.
Drug-susceptibility testing in tuberculosis: methods and reliability of results.
Eur Respir J, 25 (2005), pp. 564-569
[23]
Workshop ATS.
Rapid diagnostic test for tuberculosis; what is the appropriate use?.
Am J Respir Crit Care Med, 155 (1997), pp. 1804-1814
[24]
A Catanzaro, S Perry, JE Clarridge, S Dunbar, S Goodnight-White, PA LoBoue, et al.
The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial.
JAMA, 283 (2000), pp. 639-645
[25]
JA Caminero, M Casal, V Ausina, JM Pina, J Sauret.
Normativa SEPAR sobre diagnóstico de la tuberculosis.
Arch Bronconeumol, 32 (1996), pp. 85-99
[26]
R Vidal.
Tuberculosis y micobacteriosis.
Medicina respiratoria, 2nd ed., pp. 899-923
[27]
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America.
Treatment of tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 603-662
[28]
World Health Organization.
Treatment of tuberculosis: guidelines for national programmes, 3rd ed., World Health Organization, (2003),
[29]
JF Broekmans, GB Migliori, HL Rieder, J Lees, P Ruutu, R Loddenkemper, et al.
European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group.
Eur Respir J, 19 (2002), pp. 765-775
[30]
National Collaborating Centre for Chronic Conditions.
Tuberculosis:clinical diagnosis and management of tuberculosis, and measures for its prevention and control, Royal Collage of Physicians, (2006),
[31]
R Vidal, R Rey, A Espinar, P De March, C Melero, JM Pina, et al.
Recomendaciones SEPAR. Tratamiento y retratamiento de la tuberculosis.
Arch Bronconeumol, 32 (1996), pp. 170-175
[32]
Tuberculosis care with TB-HIV co-management: Integrated Management of Adolescent and Adult Illness (IMAI). “WHO/HTM/HIV/2007.01”, “WHO/HTM/HIV/2007.308”. Geneva: World Health Organization; 2007. p. 33.
[33]
PI Fujiwara, P Clevenbergh, RA Diodio.
Management of adults living with HIV/AIDS in low-income, high-burden settings, with special reference to persons with tuberculosis. State of the Art Series.
Int J Tuberc Lung Dis, 9 (2005), pp. 946-958
[34]
RA Diodio, PI Fujiwara, DA Enarson.
Should tuberculosis treatment and control be addressed differently in HIV-infected and uninfected individuals?.
Eur Respir J, 25 (2005), pp. 751-757
[35]
JJ Saukkonen, DL Cohn, RM Jasmer, S Schenker, JA Jereb, CM Nolan, on behalf of the ATS Hepatotoxicity of Antituberculosis Therapy Subcommittee, et al.
An official ATS statement: hepatotoxicity of antituberculosis therapy.
Am J Respir Crit Care Med, 174 (2006), pp. 935-952
[36]
CF Lacy, LL Amstrong, MP Goldman, LL Lance.
Drug information handbook, 12th ed., Lexi-Comp, (2004-2005),
[37]
Drugdex® System (Internet database).
Micromedex® Healthcare Series (Internet database), Thomson Micromedex, (2007),
[38]
A Jindani, CJ Dore, DA Mitchison.
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Am J Respir Crit Care Med, 167 (2003), pp. 1348-1354
[39]
Centers for Disease Control and Prevention.
Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005.
MMWR Morb Mortal Wkly Rep, 54 (2005), pp. 1-141
[40]
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America.
Controlling tuberculosis in the United States.
Am J Respir Crit Care, 172 (2005), pp. 1169-1227
[41]
Grupo de trabajo del área TIR de SEPAR.
Recomendaciones SEPAR. Normativa sobre la prevención de la tuberculosis.
Arch Bronconeumol, 38 (2002), pp. 441-451
[42]
Grupo de estudio del taller de 1999 de la unidad de investigación en Tuberculosis de Barcelona.
Documentos de consenso sobre tratamientos directamente observados en tuberculosis.
Med Clin (Barc), 115 (2000), pp. 749-757
[43]
CDC.
Approaches to improving adherence to antituberculosis therapy.
MMWR Morb Mortal Wkly Rep, 42 (1993), pp. 42-81
[44]
T Rodrigo, JA Caylà, H Galdós-Tangüis, P García de Olalla, MT Brugal, JM Jansà.
Proposing indicators for evaluation of tuberculosis control programmes in large cities based on the experience of Barcelona.
J Tuberc Lung Dis, 5 (2001), pp. 432-440
[45]
A Marco, JA Caylà, M Serra, R Pedro, C Sanrama, R Guerrero, et al.
Adherence to tuberculosis treatment of prisoners. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release.
Eur Respir J, 12 (1998), pp. 967-971
[46]
NR Ghandi, A Moll, AW Sturm, R Pawinski, T Govender, U Lallo, et al.
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.
Lancet, 368 (2006), pp. 1575-1580
[47]
WHO.
The global MDR-TB and XDR-TB. Response plan (20072008), WHO, (2007),
[48]
UITB.
Prevención y control de las tuberculosis importadas.
Med Clin (Barc), 121 (2003), pp. 549-562
[50]
CA Lobo Barrero, E Pérez Escolano.
Control y supervisión del enfermo tuberculoso.
Arch Bronconeumol, 38 (2001), pp. 43-47
[51]
JG Somocurcio, A Sotomayor, S Shin, S Portilla, M Valcarcel, D Guerra, et al.
Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru.
Thorax, 62 (2007), pp. 416-421
[52]
Centers for Disease Control and Prevention.
Guidelines for the investigation of contacts of persons with infectious tuberculosis;recommendations from the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.
MMWR Morb Mortal Wkly Rep, 54 (2005), pp. 1-55
[53]
British Thoracic Society Standards of Care Committee.
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-a treatment.
Thorax, 60 (2005), pp. 800-805
[54]
MJ Smieja, CA Marchetti, DJ Cook, FM Smaill.
Isoniazid for preventing tuberculosis in non-HIV infected persons.
Cochrane Database Syst Rev, 1 (1999),
[55]
S Woldehanna, J Volmink.
Treatment of latent tuberculosis infection in HIV infected persons.
Cochrane Database Syst Rev, 1 (2004),
[56]
J Ena, V Valls.
Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
Clin Infect Dis, 40 (2005), pp. 670-676
[57]
NP Spyridis, PG Spyridis, A Gelesme, V Sypsa, M Valianatou, F Metsou, et al.
The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
Clin Infect Dis, 45 (2007), pp. 715-722
[58]
Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations United States 2001.
MMWR Morb Mortal Wkly Rep, 50 (2001), pp. 733-735
[59]
A Fraser, M Paul, A Attamna, L Leibovici.
Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis.
Cochrane Database Syst Rev, 2 (2006),
Copyright © 2008. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
